Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
2.960
-0.240 (-7.50%)
At close: Oct 1, 2026, 4:00 PM EDT
3.020
+0.060 (2.03%)
Pre-market: Oct 2, 2026, 8:37 AM EDT
Ernexa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
4.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
| Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
| Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
| Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
| Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
| Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
| Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
| Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Evogene | 1.66M |
| Can-Fite BioPharma | 405.00K |
| Lexaria Bioscience | 194.00K |
| AIM ImmunoTech | 95.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Pulmatrix | 3.00K |
ERNA News
- 1 day ago - Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic - GlobeNewsWire
- 2 days ago - Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101 - TheFly
- 2 days ago - Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - GlobeNewsWire
- 2 days ago - Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting - TheFly
- 3 days ago - Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy - GlobeNewsWire
- 15 days ago - Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D. - GlobeNewsWire
- 17 days ago - Ernexa reports preliminary results for ERNA-201, to focus resources on ERNA-101 - TheFly
- 17 days ago - Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing - GlobeNewsWire